Genmab — Juli 2020
-
New Topline TEPEZZA
(teprotumumab-trbw) Data Underscore its Efficacy in Longer Disease Duration, Long-Term Durability and Potential for Retreatment in People Living with Thyroid Eye Disease (TED) https://apnews.com/792e5d2d37194348be8940fa297fcd30 -
En særmeddelelse: https://www.proinvestor.com/boards/85475
-
Tillykke Helge!!:-)
-
-
Seattle Genetics, Inc. (SGEN) CEO Clay Siegall on Q2 2020 Results - Earnings Call Transcript - on TV - https://seekingalpha.com/article/4362785-seattle-genetics-inc-sgen-ceo-clay-siegall-on-q2-2020-results-earnings-call-transcript?part=single
-
-
AbbVie- why the CD3xCD20 would be best in class - efficacy data reported puts it at higher end, safety profile has been very favourable , SC formulation, dosing schedule fits very well in the diseases we are looking at- that makes it a very strong profile
-
Det ser godt ud. Jeg må lige dykke ned i morgen.
-
Even it was expected, nice to get confirmation of the Apollo study. I see no data in the announcement, but it should form basis for approval of Dara-Pom-dex as 3rd line therapy in Europe and ROW + confirmation of the FDA approval based on the EQUULEUS phase I study
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind